PrIMAVeRa results selected for EU Innovation Radar Platform

In August 2025, the European Commission’s online Innovation Radar platform announced the inclusion of one of the “Interactive access to evidence available on burden of drug-resistant infections in Europe” of the PrIMAVeRa project as an “exploring innovation”.

The “Interactive access to evidence available on burden of drug-resistant infections in Europe”, available here, allows the end user to gain comprehensive insights into the impact of Antimicrobial Resistance (AMR) using currently available data for specific pathogen-infection combinations.  These insights can help inform decision making on pathogens and patient groups to target with novel vaccines and monoclonal antibodies (mAb). It also shows the current knowledge gaps that need to be addressed in future research.

Key innovators Université de Geneve (Dr Marlieke de Kraker, Nasreen Hassoun-Kheir MD, Prof Stephan Harbarth), Università degli Studi di Verona (Diletta Pezzani MD, Dr Fabiana Arieti, Prof Evelina Tacconelli), and Servicio Andaluz de Salud (Mariana Guedes MD, Prof Jesus Rodrigues-Bano) collaborated closely with other academic, small-medium sized enterprise, and industry partners to produce this useful tool, hosted on the ECRAID-Base EPI-Net platform. The first part is based on a comprehensive review of scientific literature, which collected data on frequency measures, health outcomes, and economic impact of drug-resistant infections for six key WHO bacterial priority resistant pathogens .  Further information about its development can be found here:  PrIMAVeRa provides in-depth reports on current evidence base of burden of AMR in Europe. Data is presented in a layered fashion, it starts with easy to understand information for a general audience. In subsequent layers more complex details are provided for experts from the field.

Alongside this, anonymized individual patient data mapped from a parallel systematic review of published studies and grey literature is also available upon request to researchers seeking to increase the coverage of the datasets within their own projects.  This data on resistant infections was sourced from scientific papers including different kinds of observational, interventional, and epidemiological studies These data are standardized and anonymised and therefore align with all FAIR principles.

The tool not only provides an overview of which data are available, but also importantly indicates which data still need to be collected to further deepen our understanding of the burden of AMR, and to refine our collective approaches in tackling this critical ongoing threat to public health and well-being.

PrIMAVeRa project partners encourage all interested parties to access and use this project output to inform and augment their ongoing actions in the battle against AMR.  The tool can be accessed here:  About PrIMAVeRa - EPI-Net

This work has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 101034420 (PrIMAVeRa). This Joint Undertaking receives support from the European Union’s Horizon 2020 research and innovation programme and EFPIA.  www.imi.europa.eu

This communication reflects the author's view and neither IMI nor the European Union, EFPIA, or any Associated Partners are responsible for any use that may be made of the information contained herein.